Robert Janssen
Dynavax Technologies Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Robert Janssen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05506969 · Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of AgeDynavax Technologies Corporation · completed · Plague, Pneumonic, Plague, Vaccine-Preventable Diseases · study chair
- Ph1NCT05245838 · Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult VolunteersDynavax Technologies Corporation · completed · Shingles, Herpes Zoster, Vaccine-Preventable Diseases · study chair
- Ph1NCT03934736 · HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing HemodialysisDynavax Technologies Corporation · completed · End Stage Renal Disease on Hemodialysis (Diagnosis) · study chair
- Ph3NCT02117934 · Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® VaccineDynavax Technologies Corporation · completed · Healthy · study director
- Ph1NCT01999699 · A Study of the Immune Response to Heplisav in Healthy Older AdultsDynavax Technologies Corporation · completed · Hepatitis B · study director
- Ph3NCT00985426 · Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) PatientsDynavax Technologies Corporation · completed · Chronic Kidney Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 42 PubMed records, and a shared surname and initials can bring in a namesake. All 42 on PubMed
- SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.Cancer Discov · 2018277 citationsRCR 8.1
- Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.J Clin Invest · 2007256 citationsRCR 6.0
- Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis.J Clin Oncol · 1992179 citationsRCR 5.1
- In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.Cancer Discov · 2018167 citationsRCR 4.9
- 161 citationsRCR 6.3
- 120 citationsRCR 5.4
- 96 citationsRCR 2.7
- Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial.Br J Dermatol · 200889 citationsRCR 3.3
- Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.Br J Cancer · 199479 citationsRCR 1.8
- 66 citationsRCR 2.0